Susan Kim-Foley
Family Medicine · Chesapeake, VANPI 1417921784
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 81 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 20.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $469 and has fallen 72.9% since, to $127 in 2023.
Across 81 payments — averaging $16.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$281
- Biohaven Pharmaceutical Holding Company Ltd.$146
- Abbott$126
- AstraZeneca$109
- Amarin Pharma, Inc.$98
- Novo Nordisk$91
- plus $515 from 19 others
What the payments were for
- Food & beverage$1,367100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 21 | $281 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $146 |
| Abbott | 7 | $126 |
| AstraZeneca | 1 | $109 |
| Amarin Pharma, Inc. | 6 | $98 |
| Novo Nordisk | 6 | $91 |
| Pfizer | 6 | $84 |
| Merck | 6 | $82 |
| Medtronic | 1 | $45 |
| Ultragenyx Pharmaceutical Inc. | 2 | $29 |
| Lilly USA, LLC | 2 | $28 |
| GSK | 2 | $26 |
| Biohaven Pharmaceuticals, Inc. | 1 | $23 |
| Astellas Pharma US Inc | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $22 |
| Boehringer Ingelheim | 2 | $22 |
| Tris Pharma Inc | 1 | $18 |
| Ironshore Pharmaceuticals Inc. | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Shire North American Group Inc | 1 | $15 |
| Scynexis, Inc. | 1 | $13 |
| Hikma Pharmaceuticals USA | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| Genentech USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$113
- BREZTRI$109
How this compares
$1,367 in reported general payments places this provider in the 70th percentile of 2,553 family medicine providers in Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Memantine Hcl ErMemantine Hcl | 12 | $4,169 |
| Raloxifene Hcl | 12 | $1,921 |
| Colesevelam Hcl | 12 | $1,298 |
| Donepezil Hcl | 12 | $1,096 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Chesapeake
- Ronald AtwoodChesapeake$15K
- Eleanor Deguzman-BerubeChesapeake$14K
- Oluwaronke AwosikaFort Gregg Adams$397K
- Monique MatuskowitzNorfolk$110K
- Paul StairsRichmond$105K
- Edwin RobinsonRichmond$83K
- Benjamin PhilpottRocky Mount$64K
- John MolaiyArlington$64K
- Catherine VarneyZion Crossroads$47K
- Jordan TranWinchester$42K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.